On November 3, 2025 Jecho Laboratories, Inc. reported it will present emerging preclinical data on JLC059, a novel GPC3/PD-L1 bispecific antibody drug conjugate (bsADC) at the 16th Annual World ADC Congress. GPC3 is a tumor-associated antigen highly expressed in liver and other solid tumors, while PD-L1 plays a key role in suppressing immune responses. JLC059 is composed of a fast-internalizing anti-GPC3 arm and a non-internalizing anti-PD-L1 arm, which enables targeted delivery of a cytotoxic payload to tumors and disrupts immunosuppressive signaling while minimizing toxicity to immune cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The World ADC Congress will be held November 3-6, 2025 in San Diego, CA.

Details on the presentation are below:

Abstract 8: JLC059, a novel GPC3/PD-L1 bsADC integrating checkpoint inhibition for enhanced anti-tumor activity

Abstract Presentation Number: 8
Session Time: Tuesday, November 4, 2025 viewing 10:00 a.m. – 5:00 p.m. PST
Location: Town & Country, San Diego

(Press release, Jecho Laboratories, NOV 3, 2025, View Source [SID1234660000])